PMID- 27146577
OWN - NLM
STAT- MEDLINE
DCOM- 20180116
LR  - 20180116
IS  - 1476-5829 (Electronic)
IS  - 1476-5810 (Linking)
VI  - 15
IP  - 3
DP  - 2017 Sep
TI  - Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia(R)) 
      in tumour bearing dogs: a phase I dose-finding study.
PG  - 919-931
LID - 10.1111/vco.12232 [doi]
AB  - Combination chemotherapy holds promise for improving outcomes in malignancy when 
      compared with single-agent approaches. Care must be taken to avoid overlapping 
      toxicity and to utilize agents with differing mechanisms of action. A phase I 
      dose-finding trial was performed to determine the maximally tolerated dose (MTD) 
      of a concurrent toceranib and doxorubicin (DOX) combination protocol where 
      toceranib dose was maintained at or near 2.75 mg kg(-1) by mouth every other day 
      (PO EOD) while escalating DOX dosage. The dose-limiting toxicity was found to be 
      neutropenia and the MTD of the combination was determined to be 25 mg m(-2) of 
      DOX q 21 days given concurrently with toceranib 2.75 mg kg(-1) PO EOD. This 
      combination was well tolerated with no excessive gastrointestinal toxicity nor 
      novel adverse events (AEs) noted. Anti-tumour activity was observed in the 
      majority of cases. This combination warrants further investigation in the context 
      of phase II/III clinical trials to characterize efficacy and long-term AE 
      profiles.
CI  - (c) 2016 John Wiley & Sons Ltd.
FAU - Pellin, M A
AU  - Pellin MA
AD  - Department of Medical Sciences, School of Veterinary Medicine, University of 
      Wisconsin-Madison, Madison, WI, USA.
FAU - Wouda, R M
AU  - Wouda RM
AD  - Kansas State University, College of Veterinary Medicine, Manhattan, KS, USA.
FAU - Robinson, K
AU  - Robinson K
AD  - Department of Medical Sciences, School of Veterinary Medicine, University of 
      Wisconsin-Madison, Madison, WI, USA.
FAU - Tsimbas, K
AU  - Tsimbas K
AD  - Department of Medical Sciences, School of Veterinary Medicine, University of 
      Wisconsin-Madison, Madison, WI, USA.
FAU - Kurzman, I D
AU  - Kurzman ID
AD  - Department of Medical Sciences, School of Veterinary Medicine, University of 
      Wisconsin-Madison, Madison, WI, USA.
FAU - Biller, B J
AU  - Biller BJ
AD  - Flint Animal Cancer Center, Colorado State University, Fort Collins, CO, USA.
FAU - Vail, D M
AU  - Vail DM
AD  - Department of Medical Sciences, School of Veterinary Medicine, University of 
      Wisconsin-Madison, Madison, WI, USA.
AD  - Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, USA.
LA  - eng
PT  - Clinical Trial, Phase I
PT  - Journal Article
DEP - 20160505
PL  - England
TA  - Vet Comp Oncol
JT  - Veterinary and comparative oncology
JID - 101185242
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Indoles)
RN  - 0 (Pyrroles)
RN  - 24F9PF7J3R (toceranib phosphate)
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - Animals
MH  - Antibiotics, Antineoplastic/*administration & dosage/adverse effects/therapeutic 
      use
MH  - Antineoplastic Agents/*administration & dosage/adverse effects/therapeutic use
MH  - Dog Diseases/*drug therapy
MH  - Dogs
MH  - Doxorubicin/*administration & dosage/adverse effects/therapeutic use
MH  - Drug Administration Schedule/veterinary
MH  - Drug Therapy, Combination/veterinary
MH  - Female
MH  - Flow Cytometry/veterinary
MH  - Indoles/*administration & dosage/adverse effects/therapeutic use
MH  - Male
MH  - Neoplasms/drug therapy/*veterinary
MH  - Neutropenia/chemically induced/veterinary
MH  - Pyrroles/*administration & dosage/adverse effects/therapeutic use
OTO - NOTNLM
OT  - Tregs
OT  - cancer
OT  - canine
OT  - chemotherapy
OT  - doxorubicin
OT  - toceranib
EDAT- 2016/05/06 06:00
MHDA- 2018/01/18 06:00
CRDT- 2016/05/06 06:00
PHST- 2016/01/05 00:00 [received]
PHST- 2016/02/22 00:00 [revised]
PHST- 2016/03/14 00:00 [accepted]
PHST- 2016/05/06 06:00 [pubmed]
PHST- 2018/01/18 06:00 [medline]
PHST- 2016/05/06 06:00 [entrez]
AID - 10.1111/vco.12232 [doi]
PST - ppublish
SO  - Vet Comp Oncol. 2017 Sep;15(3):919-931. doi: 10.1111/vco.12232. Epub 2016 May 5.